Hengehold Capital Management LLC Raises Position in Johnson & Johnson (NYSE:JNJ)

Hengehold Capital Management LLC lifted its stake in Johnson & Johnson (NYSE:JNJ) by 1.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 25,002 shares of the company’s stock after purchasing an additional 334 shares during the quarter. Hengehold Capital Management LLC’s holdings in Johnson & Johnson were worth $3,616,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of JNJ. Lifestyle Asset Management Inc. raised its position in Johnson & Johnson by 4.7% in the 4th quarter. Lifestyle Asset Management Inc. now owns 1,560 shares of the company’s stock worth $226,000 after purchasing an additional 70 shares during the period. Apeiron RIA LLC grew its stake in shares of Johnson & Johnson by 18.0% during the fourth quarter. Apeiron RIA LLC now owns 2,596 shares of the company’s stock valued at $375,000 after buying an additional 396 shares during the last quarter. Veracity Capital LLC lifted its stake in shares of Johnson & Johnson by 7.7% during the 4th quarter. Veracity Capital LLC now owns 3,343 shares of the company’s stock worth $483,000 after acquiring an additional 240 shares during the last quarter. Secure Asset Management LLC boosted its holdings in Johnson & Johnson by 31.4% during the 4th quarter. Secure Asset Management LLC now owns 5,050 shares of the company’s stock valued at $730,000 after acquiring an additional 1,206 shares during the period. Finally, Red Door Wealth Management LLC grew its position in Johnson & Johnson by 27.3% in the 4th quarter. Red Door Wealth Management LLC now owns 65,093 shares of the company’s stock valued at $9,414,000 after acquiring an additional 13,962 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of a number of recent analyst reports. Guggenheim boosted their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research note on Wednesday, November 6th. Wells Fargo & Company decreased their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research note on Thursday. Raymond James dropped their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.06.

Insiders Place Their Bets

In other news, Director Mark A. Weinberger purchased 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $146.76 on Monday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm has a market cap of $353.34 billion, a PE ratio of 22.07, a P/E/G ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The stock has a fifty day moving average price of $147.85 and a 200-day moving average price of $156.06.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22,438,500 billion. During the same period last year, the business posted $2.29 earnings per share. The firm’s revenue was up 5.3% compared to the same quarter last year. Equities research analysts predict that Johnson & Johnson will post 10.56 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.38%. Johnson & Johnson’s payout ratio is 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.